The recently cloned functional thrombin receptor is thought to be activated by thrombin cleavage of the bond between R41 and S42, followed by the insertion of the new N-terminal region ("tethered ligand") into an unknown site in the receptor. Antibodies to peptides at or near the cleavage site have been reported to inhibit thrombin-induced platelet activation to varying extents, but the precise mechanism(s) of their inhibition is unknown. We have produced: (1) a polyclonal antibody in rabbits to a peptide containing amino acids 34 to 52 (anti-TR34-52); enzyme-linked immunosorbent assays (ELSA) indicate that anti-TR34'52 contains antibodies to regions on both sides of the thrombin cleavage site; (2) two murine monoclonal antibodies (MoAbs) to a peptide containing amino acids 29 to 68; one antibody reacts primarily with residues N-terminal to the thrombin cleavage site, and the other reacts primarily with residues C-terminal to the cleavage site; and (3) a polyclonal rabbit antibody to a peptide containing amino acids 83 to 94 (anti-TR8"%). Anti-TRj4-52 binds to platelets as judged by flow cytometry, and pretreating platelets with a thrombin receptor peptide ligand does not lead to loss of antibody reactivity, suggesting that platelet activation does not initiate redistribution or internalization of surface thrombin receptors. In contrast, pretreating plate-HROMBIN IS A serine protease that acts as a potent T agonist for platelet activation, secretion, and aggrega-
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The identification of the thrombin receptor on platelets has been a long sought after goal, resulting in the identification of multiple thrombin-binding proteins and thrombin substrate^,^-'^ but an understanding of the signal transduction pathway(s) has remained elusive. Thrombin displays unusual activation kinetics in that an active catalytic site is required for inducing platelet aggregation whereas a concentration-dependent response suggests that receptor-occupancy is As a result, several models of platelet-thrombin interaction have been proposed.
Recently, Vu et all4 cloned a thrombin receptor derived from mRNA of HEL and DAM1 cells, which are thrombinresponsive, megakaryocyte-like cell lines, by expressing the active receptor in Xenopus oocytes. This receptor is a member of the G protein-linked seven transmembrane domain receptor family. Their proposed model of thrombin receptor activation suggests that thrombin binds to a region of the receptor that is homologous to hirudin via thrombin's anion-binding exosite, and then thrombin's catalytic site cleaves the peptide bond between arginine residue 41 and serine residue 42 of the receptor. The newly exposed N-terminus acts as a tethered ligand that interacts with another, unidentified region of the receptor and initiates signal transduction. They further showed that a 14 amino acid peptide representing the new N-terminus could stimulate platelet aggregati~n.'~ Recently, Hung et all' produced polyclonal lets with thrombin leads to complete loss of anti,-TR"-52 binding. Similarly, the binding of both MoAbs to platelets is dramatically reduced by pretreatment with thrombin. However, the binding of anti-TR83-s4 is not decreased by thrombin activation, confirming that the receptor is not internalized. Anti-TR34-5z profoundly inhibits low dose thrombin-induced platelet shape change and aggregation, but the inhibition can be overcome with higher thrombin doses. However, anti-TR34-52 does not inhibit platelet aggregation induced by tethered ligand peptides. The TR34-52 peptide is a thrombin substrate, with cleavage occurring at the R41-S42 bond as judged by high performance liquid chromatography (HPLC) and platelet aggregation analysis. Anti-TR34-52 prevented cleavage of the TRJe5' peptide, suggesting that the antibody prevents platelet activation, at least in part, by preventing cleavage of the thrombin receptor. These data, although indirect, provide additional support for a thrombin activation mechanism involving thrombin cleavage of the receptor; in addition, they provide new evidence indicating that receptor cleavage is followed by loss of the N-terminal peptide, and insertion of the tethered ligand into a protected domain. antibodies to an 18 amino acid peptide from the hirudinlike domain (peptide 360-1; amino acids 52 to 69 + Cys) (Fig 1) and showed that it specifically blocked low-dose thrombin-induced platelet aggregation and secretion, but not activation by the 14 amino acid peptide ligand (amino acids 42 to 55) from the thrombin receptor. The presumed mechanism of inhibition was prevention of thrombin binding to the receptor. These authors also produced antisera to an 18 amino acid peptide (359-1; amino acids 29 to 45 + Cys) that contained 13 amino acids N-terminal to the presumed thrombin cleavage site, 4 amino acids C-terminal to 
S F L L R N P N D K Y E P F-NH2
TR42-55 the cleavage site, and an additional cysteine. Two of three such antisera caused partial inhibition of thrombin-induced platelet activation, and the third had no inhibitory activity. They speculated that the partial inhibition was caused by prevention of agonist peptide function and/or inhibition of receptor cleavage, but no direct data were reported.
TR34-52
Brass et all6 most recently prepared monoclonal antibodies (MoAbs) to the 14 amino acid peptide ligand (amino acids 42 to 55). Three of the antibodies (ATAP2, ATAP 120, and ATAP 1 38) inhibited platelet aggregation induced by a-thrombin, y-thrombin, and trypsin, but not adenosine diphosphate (ADP), epinephrine, or the thromboxane analogue U466 19. The inhibition of thrombin-induced platelet activation could be overcome by increasing the thrombin concentration. One of the antibodies (ATAPl38) was tested for its ability to inhibit aggregation induced by a 6 amino acid receptor peptide ligand (SFLLRN; amino acids 42 to 47); no inhibition was observed. Approximately 1,800 molecules of ATAPl38 bound per platelet at saturation. Studies were not conducted to assess whether the antibodies interfered with the cleavage of the receptor, interfered with the binding of the tethered ligand into its proposed receptor site, or interfered with both processes.
We have recently, briefly described a polyclonal rabbit antibody to a 20 amino acid synthetic peptide corresponding to amino acids 34 to 52 of the thrombin receptor (with the addition of an N-terminal cysteine for purposes of crosslinking) that contains eight amino acids N-terminal, and 1 1 amino acids C-terminal, to the thrombin cleavage site (TR34-52) (Fig I) .'7 This antibody ( a r~t i -T R~~-~* ) profoundly inhibits platelet aggregation induced by low concentrations of thrombin and partially inhibits thrombin-induced shape change, but has little or no effect on aggregation induced by the thrombin peptide.I7 In the present study, we have localized the regions of antibody reactivity with an enzymelinked immunosorbent assay (ELISA), assessed the thrombin inhibition dose-response relationship, analyzed the antibody's reactivity with untreated and thrombin-treated platelets by flow cytometry, and directly determined that the antibody can inhibit thrombin-induced cleavage of the TR34-52 peptide. In addition, we report on the binding of two murine MoAbs that react primarily with epitopes on either side of the thrombin cleavage site, and a polyclonal antibody directed against a peptide containing amino acids 83 to 94 of the thrombin receptor. The binding patterns of these antibodies to resting and thrombin-activated platelets provide insights into the mechanism by which the thrombin receptor is activated.
MATERIALS AND METHODS

Polyclonal Antibody Studies
All chemicals were of reagent grade from either Sigma Chemical (St Louis, MO) or Fisher Scientific (Fairlawn, NJ) unless otherwise specified. Hirulog-1, a high affinity inhibitor of thrombin," was a gift from Dr John Maraganore of Biogen (Cambridge, MA). Purified human thrombin (3,500 U/mg) was agift from Dr Jolyon Jesty, State University of New York at Stony Brook." Partially purified human thrombin was obtained from Sigma (St Louis, MO). Antibody s-12, a murine MoAb directed against P-selectin (GMP-140),' was a gift of Dr Rodger McEver, University of Oklahoma. Antibody IOE5, a murine MoAb to glycoprotein Ilb/IIIa (GPIIb/ IIIa), has been previously described."
Blood was drawn from healthy volunteers into 0.37 volume of EDTA (269 mmol/L) for flow cytometry studies, or either 0.14 volume of acid-citrate dextrose (ACD-A; 0.12 mol/L dextrose, 0.075 mol/L Na, citrate, 0.038 mol/L citrate, pH 5.0 to 5.1) or 0.01 volume 40% Na, citrate for platelet aggregation studies. Platelet-rich plasma (PRP) was prepared by centrifugation at 700g for 4 minutes at 22°C. Gel-filtered platelets (GFP) for platelet aggregation were prepared by: adding 0.1 volume ACD-A to the PRP and centrifuging at 1,OOOg for IO minutes at 22°C; resuspending the pellet in 600 ILL of Hepes-buffered modified Tyrode's solution (HBMT, I O mmol/L HEPES, 138 mmol/L NaCI, 2.7 mmol/L KCI, 12 mmol/L NaHCO,, 0.4 mmol/L NaH,PO,, 0.1% wt/vol dextrose, 0.2% wt/vol bovine serum albumin [BSA], pH 7.4); and gel-filtering through a 20-mL Sepharose-2B (Pharmacia, Piscataway, NJ) column. The cloudy, white platelet peak was collected and the platelet count determined using a Coulter Counter (Model ZM, Hialeah, FL). MgCI, was added to the platelet eluate at 2.0 mmol/L final concentration.
The TR'"'' peptide was synthesized on a solid phase synthesizer (Model 430A; Applied Biosystems, Foster City, CA) using t-Boc chemistry; a 4-methylbenzhydrylamine (4-MBHA) resin was used to produce a C-terminal amide after cleavage. The amino acids T, N, R, and Y were double-coupled to ensure incorporation. The peptide was cleaved from the Blood preparation.
Production of antibodies.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From resin with hydrofluoric acid in the presence of anisol, dimethysulfide, and pthiocresol(l0: 1: 1:0.2 by volume, respectively). The resin was washed with ether and dichloromethane, and then extracted in acetic acid and lyophilized. The pH of the peptide was raised to 10 and then lowered to 3 to reverse any N + 0 shift of the serine or threonine residues and then purified on a C8 reverse-phase high performance liquid chromatography (HPLC) column with a water:acetonitrile buffer system containing 0.1% trifluoroacetic acid, using a gradient from 0% to 60% acetonitrile over 40 minutes; analytical C8 reverse-phase HPLC showed that 79% of the optical density was in the major peak. In a likewise manner, the following peptides were synthesized a 12 amino acid peptide (QLPAFISE-DASG; TR8*94), as well as the same peptide with an N-terminal cysteine, whose sequence was derived from a region in the first extracellular domain of the thrombin receptor, near the membrane spanning domain; and an 1 1 amino acid peptide (SFLLRNPNDKY, TR42-52) and a 14 amino acid peptide (SFLLRNPNDKYEPF ), whose sequences were derived from the newly exposed N-terminus of the thrombin receptor after cleavage by thrombin. Analytical HPLC of these peptides showed at least 58% of the total optical density in the major peaks.
and TR83-94 were coupled to keyhole limpet hemocyanin (KLH) with the chemical cross-linker mal-sac-HNSA (Bachem Inc, Philadelphia, PA). Amino groups on KLH were linked to the aminocaproyl ester of the mal-sac-HNSA reagent and then the maleamide group of the mal-sac-HNSA reagent was linked to the sulfhydryl groups on the N-terminal cysteine residues. KLH (Calbiochem Inc, La Jolla, CA) was dissolved in phosphate buffered saline (PBS 10 mmol/L Na phosphate, 150 mmol/L NaCl pH 7.4) at a final concentration of 6 mg/mL. Mal-sac-HNSA was dissolved in PBS at a concentration of 10 mg/mL and 0.3 volume was added to the KLH. The reaction was allowed to proceed for 2 to 2.3 hours at 22°C and terminated by gel filtration over a G-10 or G-25 Sephadex column (Pharmacia), equilibrated with PBS, pH 6.0 or 7.4, to separate the modified KLH from unreacted mal-sac-HNSA. For TRws2, the peptide was dissolved in PBS (pH 6.0) at a concentration of 20 mg/mL and a trace amount of 'z51-TR3452 (see below) was added to allow quantitation of peptide incorporation. A 50-fold molar excess of dithiothreitol (DTT) was added to the peptide to fully reduce the cysteine sulfhydryl. After 10 minutes, the peptide mixture was applied to a G-25 Sephadex column equilibrated with degassed PBS, pH 6.0, to separate reduced peptide from excess DTT. Eluted fractions were assessed by measuring optical density at 280 nm, radioactivity, and the concentration of free sulfhydryl groups using 5,5' dithio-bis(2-nitrobenzoic acid) (Ellman's reagent; Pierce, Rockford, IL). Peptide fractions were pooled and added to the modified KLH. For TR83-94, 5.0 mg ofpeptide dissolved in PBS, pH 7.4, was reacted with the pooled fractions of modified KLH. Both reactions were allowed to proceed 2 hours at 22°C and terminated by dialysis against PBS, pH 7.4. Completion of the reactions was monitored by assessing the concentration of remaining free sulfhydryl groups. As judged by the incorporation of the radioactive peptide, 0.9 mg of peptide TR3's2 was incorporated per mg of KLH.
also was coupled to KLH using glutaraldehyde to crosslink amino groups in the KLH to the t-amino group of the lysine residue in TR3452 as described by Doolittle.22 KLH, (20 mg/0.5 ml), unlabeled peptide (1 5 rmol in 1.5 mL H20), and a trace amount of were dissolved in 0.4 mol/L phosphate, pH 7.4, and glutaraldehyde (1 mL of 20 mmol/L) was added dropwise over 5 minutes at 22°C. Residual glutaraldehyde was quenched by reaction with 1 mol/L glycine (0.25 mL) and the reaction was then terminated by dialysis against PBS, pH 7. poration of the radioactive peptide, 70% of the peptide was coupled to the KLH.
The two TR3"52-KLH antigens were first mixed 1 : 1 by peptide mass and then mixed 1:2 (vo1:vol) with either complete Freund's adjuvant (for initial immunization) or incomplete Freund's adjuvant (for subsequent immunizations); the TR3452 mixtures were then sonicated for 1 minute at 4°C in 15-to 20-second bursts (Wave Energy Systems model MT-1; Lab-line Ultratop Labsonic System #9 100, Melrose Park, IL); the TRs3-94 peptide was manually homogenized 1: 1 (vo1:vol) in complete Freund's adjuvant (first immunization) or incomplete Freund's adjuvant (subsequent immunizations) by rapid transfer between two IO-mL syringes. New Zealand white rabbits were injected on day 1 with 1 mg of peptide and on days 8 and 15 with 0.5 mg ofpeptide. On day 22, sera were obtained for analysis and on day 29 the rabbits were exsanguinated. The sera with the highest activities, ~II~~-TR'"~' and anti-TR83-94, were chosen for further investigation.
Peptide ELISA assuys. The wells of microtiter plates (#3915; Bio Rad Laboratories, Richmond, CA) were coated with TR3452 peptide, TR83-94 peptide (100 pg/mL; 100 pL/well) or BSA (0.5%; 100 pL/well) in 0.05 mol/L carbonate buffer, pH 9.5, for 1 hour at 37°C. Any remaining binding sites on the plates were blocked with 0.5% BSA in Tris-saline-azide (TSA, 0.01 mol/L Tris/HCl, 0.15 mol/L NaCI, 0.05% NaN,, pH 7.4) for at least 1 hour at 22°C or overnight at 4°C. Serum or purified antibody was added to the wells at various dilutions and allowed to incubate for 2 hours at 22°C. After extensive washing with TSA containing 0.05% Tween-20, goat antirabbit-alkaline phosphatase-conjugated antibody ( 100 pL/ well; l/5,000 to l/lO,OOO dilution in TSA; Tago, Burlingame, CA) was added and allowed to incubate 2 hours at 22°C. The plate was washed extensively with TSA-0.05% Tween-20 and then the phosphatase substrate (100 pL/well; 2 mg/mL p-nitrophenyl phosphate disodium in 0.1 mol/L NaHCO,, 0.01 mol/L MgCl,, pH 9.5; Sigma Chemical Co, St Louis, MO) was added. The optical density (OD) was measured at 405 nm in a microplate reader (V,,,, Molecular Devices, Menlo Park, CA). In some experiments, anti-TR34-52 serum or purified antibody was preincubated with free TR34-52, TR42-52, or the unrelated peptide Arg-Gly-Asp-Phe (RGDF) (20 nmol/L to 200 pmol/L), for 1 hour at 22°C before adding it to the plate. The ability of the free peptide to inhibit antibody binding to the immobilized peptide was measured by the decrease in optical density compared to a control in which buffer was added to antibody instead of peptide.
Epitope mapping. To assess the reactivity of the at~ti-TR~"~' with different regions of the external sequence of the thrombin receptor, epitope mapping was performed by an ELISA technique using peptides whose sequences were derived from the thrombin receptor, beginning at the N-terminus of the protein after cleavage of the proposed signal peptide, and including all three extracellular loops (amino acids 26 to 99, 16 1 to 176,240 to 265 and 336 to 347, respectively). In all, 49 overlapping decapeptides, each offset by two amino acids, were synthesized by t-Boc chemistry onto solid-phase supports coupled to polypropylene pins (Multi-Pin System, Chiron Mimotopes Ltd, Clayton, Victoria, Australia). The N-termini of all of the peptides were acetylated. The pins are held in a rack that allows them to fit loosely into the wells of a microtiter plate, thus facilitating sequential incubations with reagents.
The ELISA assay was performed using purified anti-TR34-S2 IgG or purified normal rabbit serum (NRS) IgG and peroxidase-labeled goat antirabbit IgG (heavy and light chain specific; Jackson Immunoresearch, West Grove, PA). The polypropylene pins with covalently coupled peptides were placed into the wells of a microtiter plate (Falcon 39 15; Becton Dickinson, Lincoln Park, NJ) contain- at 100 rpm. The pins were removed from the precoat buffer, excess buffer was flicked off, and the pins were placed into wells containing 175 pL of either purified anti-TR3"" IgG or NRS IgG diluted to 67.0 pg/mL in precoat buffer. After 1 hour ofshaking at 100 rpm at 2 2 T , the pins were washed three times, each for 10 minutes in PBS, pH 7.2. The pins were then placed into wells of a microtiter plate containing 175 pL of the peroxidase-labeled goat antirabbit IgG diluted 1:5,000 in sheep serum buffer (1.0% vol/vol sheep serum (Sigma), 0.1% vol/vol Tween 20 in PBS, pH 7.2) and the plate was rotated at 22°C for 60 minutes at 100 rpm. The pins were washed three times at 22°C for 10 minutes per wash and then placed in the wells of a microtiter plate containing 150 pL of substrate solution (0.5 mg/mL diammonium 2,2'-azino-bis[3-ethylbenzthiazoline-6-sulfonate] [ABTS] [Sigma], 0.0 I % wt/vol hydrogen peroxide [Sigma] in 0.1 mol/L Na,HPO,, 0.08 mol/L citric acid, pH 4.0) The plate, with the pins remaining in the wells, was rotated at 22°C for 3 minutes at 100 rpm. The optical density was read at 405 nm and 490 nm in an ELISA plate reader (Molecular Devices), and the 490-nm value was subtracted from the 405-nm value to correct for background. Data were calculated as the difference in optical density between the anti-TR3'" and the NRS for each peptide.
Removal of the antibody fiom the pin peptides.
To reuse the peptides on the pins, the previous reactants had to be removed. The pins were placed in a sonicator bath (Sonicor, Copiague, NY) containing 0.1 mol/L sodium phosphate with 1% wt/vol sodium dodecyl sulfate (SDS) (Fisher Scientific) and 0. l % 2-mercaptoethanol (Pharmacia LKB Biotechnology), pH 7.2, at 60°C. The pins were sonicated (3 kW/mz at 60 kHz) for 10 minutes and rinsed twice with distilled water preheated to 60°C. The pins were then washed in a bath of distilled water at an initial temperature of 60°C for 30 minutes with agitation. After shaking off excess water, the pins were immersed in boiling methanol (Fisher) for 15 to 30 seconds and allowed to air dry for 15 minutes. The pins were then placed into substrate solution and the optical density was measured in an ELISA plate reader after 45 minutes to assay for the presence of any remaining conjugate. If the antibody was successfully removed, the pins were stored in a plastic bag with dessicant at 4°C. If residual conjugated antibody was detected, the procedure was repeated.
Purijcation of antibody. Control and immune sera were heated to 56°C for 1 hour and delipidated by adding 1 volume of Seroclear (Calbiochem Inc) to 1.5 volume of serum and centrifuging at 1, OOOg for 15 minutes at 22°C. The supernatant was filtered through a 0.45 p filter (Genex Inc, Gaithersberg, MD), diluted to 20% with starting buffer (10 mmol/L NaPO,, 1.5 mol/L NaC1, pH 8.5) and applied to a 10 mL Protein A Sepharose column (BioProbe International, Tustin, CA). After washing the column in starting buffer, IgG was eluted either in two steps (pH 5 and pH 3) or one step (pH 3.5) using a 0.1 mol/L citrate buffer. The eluting fractions were collected in tubes containing sufficient 1 mol/L Tris/HCI (pH 9.5) to immediately neutralize the pH. Fractions containing IgG were dialyzed against TSA. Purified IgG was assessed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as described by Laemmliz3; protein concentration was estimated by optical density at 280 nm using A& = 14.
F(ab'), fragments of normal rabbit serum IgG (NRS) and antiTRWs2 IgG were produced by overnight incubation of IgG with 0.5% (wt:wt) pepsin (Worthington Biochemical, Freehold, NJ) in 0.2 mol/L NaCI, 0.2 mol/L NaCI, pH 4.0 at 37°C. The reaction was terminated by dialysis against TSA.
Flow cytometry analysis. Aliquots of EDTA PRP or GFP(Sepharose 2B; 0.15 mol/L NaCI, 0.01 mol/L Tns/HCI, 0.01 mol/L EDTA, pH 7.4 (TSE); 3 to 4 X 10' platelet/mL) were incubated with buffer or various concentrations (100 to 500 pg/mL) of purified IgG or F(ab'), fragments of NRS, anti-TR"", or anti-TRS*94 (primary antibodies); a control polyclonal rabbit antithrombocyte serum (final dilution 1/200; Accurate Chemical, Westbury, NY) was also used in some experiments as a positive control. After 20 to 30 minutes at 22"C, the platelets were washed twice in 1.8 mL TSE and resuspended to 400 pL in TSE. Each sample was then incubated with affinity-purified, fluorescein isothiocyanate (FITG)-conjugated, F(ab), fragments of goat antirabbit F(ab'), fragment (Jackson Immunoresearch) so that the final dilution was 1/100. After 20 to 30 minutes at 22"C, the platelets were washed once in 1.8 mL TSE buffer, resuspended to 1 .O mL in TSE, and then evaluated by flow cytometry.
For thrombin digestion studies, GFP (3 to 4 X 10' platelet/mL) in TSE was incubated at 37°C for 5 minutes with 0.1, 1.0, or 10 U/mL human purified thrombin. The reaction was terminated by addition of 50-fold molar excess of Hirulog for 5 minutes at 37°C; primary antibody was then added and the samples were processed as above. In other studies, GFT was incubated with TR4"" (-50 pmol/L) to activate the platelets for 5 minutes at 37°C before adding the primary antibody and processing as above. In some experiments, aliquots of GFP were incubated 30 minutes with primary antibody before the addition of thrombin or TR42-55.
Flow cytometry analysis was performed on a FACStar analyzer (Becton-Dickinson, San Jose, CA) using a 70 p aperture and an argon laser at 200 mW (Innova 90; Coherent Laser Products, Palo Alto, CA). Data analysis was performed with the Lysys I1 program supplied by the manufacturer and each analysis consisted of lo4 platelets. Before analysis, platelets that were treated identically to the experimental samples except for receiving buffer instead of either antibody were analyzed by forward angle light scattering in order to gate 90% of the single platelet population.
Cleavage of TR"' ' and 1'sI-TR34'5z by thrombin. Reduced and alkylated TR3b52 (see below) (1 mg/mL) was incubated with thrombin (1 U/mL) for I hour at 37°C and then Hirulog (50 pg/mL final concentration) was added to stop the reaction. Trichloroacetic acid (10% final concentration) was then added at 4°C to precipitate the thrombin but not the peptides, and after 60 minutes the solution was centrifuged at I2,OOOg for 3.5 minutes at 22°C. Cleavage of TR3452 was assessed by reverse-phase HPLC as above, using uncleaved TR"" and TR4"" as standards. To test the effect of the anti-TR"" antibody on thrombin cleavage of TRWs2, a trace dose of 12sI-TR34s2 was incubated with either anti-TR"" F(ab), or NRS F(ab')2 ( 1 mg/mL) and the cleavage was performed as above. The HPLC fractions were counted in a gamma spectrometer (Autogamma model 5550: Packard Instrument Co, Meriden, CT) and the identification of the 12sI-TR34~52 cleavage products was facilitated by adding some of the unlabeled TR3"" cleavage products so that they could be identified readily on the HPLC optical density profile.
Platelet aggregation andshape change. Platelet aggregation was performed as previously described using PRP or GFP." To avoid the confounding effects of platelet aggregation, studies of platelet shape change were performed on platelets pretreated for 15 minutes with either 10 mmol/L EDTA or a saturating (25 pg/mL) dose of the murine MoAb 10E5, which binds to the platelet GPIIb/IIIa receptor and prevents platelet aggregation."
TR3"" peptide and TRWS2 peptide that had been reduced (0.35% 2-mercaptoethanol for 60 minutes at 22°C) and alkylated (60 mmol/L iodoacetamide, pH 8.0, for 60 minutes followed by gel filtration
Iodination of TR""' and reduced and alkylated TR34-'2.
For -25 column) to prevent dimerization, were radiolabeled with '''I using glass vials coated with 50 pL of 5 mg/mL Iodogen (Pierce). Radiolabeled peptide was separated from unincorporated "' I by gel filtration over a Sepharose G-15 column with TSA. 12sI-TR3'52 was used to monitor the efficiency of peptide coupling to KLH and the reduced and alkylated 1251-TR3452 was used to follow the cleavage of the peptide in solution by thrombin.
Monoclonal Antibody Studies
Synthetic peptides. Thrombin receptor peptides, PESKAT-NATLDPRSF, TR29-43; SFLLRNPNDKYEP, TR42-54; PFWEDE-EKNESGL, TR5466; and PESKATNATLDPR-SFLLRNPND-KYEPFWEDEEKNESGLTEC, TR29-68 (with an added C-terminal cysteine) were prepared using standard solid-phase t-BOC chemistry using an Applied Biosystems Model 431A peptide synthesizer using the manufacturers instructions (TR2943, TR42-54 , and TR5466) or with standard FMOC chemistry using an Applied Biosystems Model 430A peptide synthesizer (TR29-68). The peptides were prepared with free carboxyl groups and the N-terminal amino groups were not acetylated. Completed peptides were released from their resins and deprotected using standard anhydrous hydrogen fluoride (HF) conditions for the t-BOC prepared resins and trifluoroacetic acid protocols for the FMOC prepared resin. Crude peptides were purified to homogeneity using C,,-reversed-phase liquid chromatography and amino acid sequences confirmed using an Applied Biosystems 473A protein sequenator using the manufacturer's protocols.
Peptide conjugation, immunization, and MoAb production. TR29-68 was coupled to KLH using m-maleimidobenzoy1-Nhydroxysulfosuccinimide ester (Sulfo-MBS Pierce). Three BALB/c mice (Simonsen, Gilroy, CA), were injected intraperitoneally four times with the antigen conjugate (100 pg/mice). After a period of 8 weeks, sera from immunized animals were tested for reactivity against the antigen by ELISA (see below). Responsive animals were killed by cervical dislocation and the spleens removed. Spleen cells (1 X IO8) were fused with P3X cells (3 X IO') using 50% polyethylene glycol (PEG) in RPMI 1640 medium. Fused cells were diluted in RPMI selection medium containing hypoxanthine (100 pmol/ L), aminopterin (0.4 pmol/L) and thymidine (16 pmol/L), and aliquoted into 96-well plates (Costar, Cambridge, MA). After 2 weeks of culture, supernatants from each well were screened in the ELISA assay described below and positive hybridomas were cloned by limiting dilution.
Primary hybridoma screening was done by ELISA using the TR29-68 peptide coated onto the wells of 96-well plates. Peptide ( I O pg/mL) in sodium borate buffer (50 mmol/L, pH 8.6, 100 pL/well) was allowed to absorb to the wells overnight at 4°C. The plates were subsequently blocked for 1 hour at room temperature (4% BSA/PBS), and washed three times (PBS containing 1% BSA and 0.1% Tween-20; 200 pL/well). Mouse serum, hybridoma medium, or purified antibody was then added to the wells (100 pL/well) at room temperature for 2 hours. The wells were washed three times, followed by the addition of goat antimouse IgG conjugated to horseradish peroxidase, diluted 1:2,000 in washing buffer; after incubation at room temperature for I hour, the wells were washed and the assay developed with ABTS substrate (1 mg/mL in 0.1 mol/L citric acid, 0.1 mol/L Na2P04, pH 4.0), followed by the addition of H20, (1 : 10,000 dilution) for 15 minutes. The reaction was stopped with 5% SDS and read in an ELISA reader at 560 nm. The same methods were used to determine the immunoreactivity of hybridomas or purified antibodies with the peptide fragments TR294343, TR42-54 , and TR5G6.
Antibody screening and epitope characterization.
Ascites production, antibody purification, and antibody iodination. Ascites enriched in the MoAbs was prepared by intraperitoneal injection of Pristane-pretreated BALB/c mice. Antibody was purified from the ascites by affinity chromatography on protein A-Sepharose. Iodination of antibody with Iz5I was performed with immobilized chloramine-T (IODO-Beads; Pierce). The specific activity was -1,180 cpm/ng.
Binding of '251-antibodies to GFP. Platelets were isolated from human blood on the day of use by gel filtration. In a typical experiment, 60 mL ofblood was collected into 8.7 mL of ACD (85 mmol/ L sodium citrate, 1 1 1 mmol/L dextrose, 7 1 mmol/L citric acid) containing 50 ng/mL PGI, , and centrifuged for 20 minutes at 160g. PRP was removed and centrifuged for 10 minutes at 730g at room temperature to sediment the platelets. The resulting platelet pellet was resuspended in 5 mL of Buffer A ( I 2 mmol/L sodium bicarbonate, 10 mmol/L HEPES, 138 mmol/L NaCI, 5.5 mmol/L glucose, 2.9 mmol/L KCI, and 0.35% human serum albumin, pH 7.4) and applied to a 40-mL Sepharose C1-2B column ( I .5 X 23 cm; Pharrnacia) in the same buffer. Platelets were collected from the column in the void volume to remove plasma proteins. In some experiments, the platelets were incubated with EDTA (1 mmol/L), EDTA + ADP (20 pmol/L), or EDTA + thrombin (0.05 U/mL; Hematologic Technologies, Inc, Essex Junction, VT) for 10 minutes at 37°C. For the antibody binding experiments, platelets (0.5 to I .O X IO8 platelets/mL) were incubated with lZsI-antibodies for 45 minutes at room temperature. After binding, 100 pL aliquots of each sample were layered onto 0.5 mL of 20% sucrose in buffer A containing 2 mmol/L CaC1, and 2 mmol/L MgCI, and centrifuged for 2 minutes at 12,000g in a microfuge to separate free 125~-antibody from '*'I-antibody bound to platelets. The 1Z51-antibody associated with the platelets was determined by clipping off the tip ofthe microfuge tube and counting in a y counter. Data from binding experiments were used to determine the dissociation constant (KJ as determined by the method of Scatchard using the computer program LIGAND?4
RESULTS
Polyclonal Antibodies
Anti-TR3"52 serum reacted positively (OD405 2 0.2) in the ELISA assay using immobilized TR34-SZ at dilutions of serum as high as 1/12,800 (corresponding to -0.78 pg/mL IgG), whereas similar dilutions of control preimmune serum failed to produce any positive signal. Anti-TR3"52 did not react with a BSA substrate. The specificity of the interaction of anti-TR34-52 with immobilized TR3"" was tested by preincubating the antiserum with TR34-52, TR4*-52 , or an unrelated RGDF peptide. TR34-52 at 200 pmol/L final concentration reduced the optical density produced by the 1/1,600 serum dilution by 83%; dose-response inhibition was seen at lower peptide concentrations. In contrast, TR42-52 was able to block only 50% of the reactivity even at 200 pmol/L, and a similar dose-dependency was noted at lower concentrations. This suggests that anti-TR3'" contains antibodies directed at sequences on TR3"" that are both N-terminal and C-terminal to the thrombin cleavage site. The unrelated RGDF peptide at identical concentrations failed to show any inhibitory activity. In further specificity testing, antiserum prepared against the protein vitronectin did not bind to immobilized TR3"" and neither TR3'52 nor TR42-52 in-
Characterization of ~n t i -T R~~-~' by ELISA.
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From hibited antivitronectin serum from binding to purified vitronectin. F(ab'), fragments of anti-TR3452 gave ELISA results that were similar to those observed with the intact antibody.
Epitope mapping. Anti-TR34-52 gave strong signals (OD,,, > 0.70) in the pin ELISA with the decapeptides containing the sequences 32 to 40 through 47 to 56 ( Table I) . All of these peptides contain amino acid sequences in the immunizing peptide (TR34-52). Only one of the peptides containing sequences from the other external domains of the thrombin receptor bound enough anti-TR3452 to give a strong positive signal, and three other isolated peptides gave weak signals. It is unlikely that any of these four positives represent sequence-specific binding because the peptides immediately preceding and succeeding the positives did not give positive responses, despite having the same sequence in 8 of 10 amino acids. Because some of the peptides giving a positive ELISA response contain amino acids that are only N-terminal to the thrombin cleavage site at R4 I-S42 (eg, amino acids 32 to 40), and others contain sequences that are only C-terminal to the thrombin cleavage site (eg, amino acids 43 to 52), these data provide additional support for the presence of antibodies to regions on both sides ofthe thrombin cleavage site in anti-TR34-52.
Functional characterization of ~n t i -T R '~"~.
As previously described," intact anti-TR34-52 IgG at 63 pg/mL and anti-TR34-52 F(ab'), fragments at 125 pg/mL completely inhibited platelet aggregation induced by 0.4 U/mL thrombin in citrated PRP and 0.1 U/mL thrombin in GFP (Fig 2A) . Control NRS IgG or F(ab), fragments at similar concentrations either did not inhibit platelet aggregation at all or produced only minimal inhibition. The inhibitory effects of anti-TR3"52 on aggregation could be partially overcome by increasing the thrombin concentration (Fig 2B) . Doubling the antibody concentration did not further inhibit the response induced by the higher thrombin concentrations. The inhibition of platelet aggregation produced by anti-TR3",' was thrombin-specific, as neither intact anti-TR3"5Z nor F(ab'), fragments of anti-TR3"52 had any effect on ADP-induced platelet aggregation (1 5 pmol/L) (data not shown). Anti-TR3"52 at concentrations that inhibited thrombin-induced platelet aggregation did not inhibit shape change or aggregation induced by the thrombin receptor peptide ligand TR42-52 (data not shown).
Platelet shape change induced by thrombin was assessed in PRP in the presence of 10 mmol/L EDTA or saturating doses of 10E5 to prevent platelet aggregation. Anti-TR34-52 F(ab), partially inhibited thrombin-induced shape change when compared with the NRS F(ab), control (Fig 3) . This inhibition could aIso be partially overcome by increasing the concentration of thrombin.
At least two potential mechanisms could account for the ability of anti-TR34-52 to inhibit thrombin-induced platelet aggregation: ( 1) inhibition of thrombin-induced cleavage of the thrombin receptor, and/or (2) inhibition of the tethered ligand's insertion into its presumed binding site on the thrombin receptor as a result of antibody binding to the tethered ligand region. To assess whether anti-TR34-52 could inhibit thrombin-induced cleavage of the thrombin receptor, we tested its ability to prevent cleavage of the TR34-52 peptide by thrombin. The reduced and alkylated TR3"52 peptide (1 mg/mL) functioned as a thrombin (1 U/mL) substrate: it was nearly completely cleaved into two fragments after 1 hour at 37"C, one of which eluted on HPLC in a position essentially identical to the TR4"52 peptide, whereas the other, presumably representing the nine amino acid Nterminal peptide, eluted more rapidly. The TR42-52 generated by thrombin cleavage of TR34-52 was able to aggregate platelets at doses comparable to authentic TR42-52, whereas TR3"*' could not aggregate platelets (data not shown). In the presence of 1 mg/mL control F(ab), fragments, thrombin was still able to cleave the radiolabeled TR34-52 extensively, with 69% of the radioactivity migrating with the ~~4 2 -5 2 peak instead ofthe TR3"52 peak (Fig 4) . However, in the presence of 1 mg/mL anti-TR3'52 F(ab), fragments, only -9% of the radioactivity was found in the TR42-52 peak.
Flow cytometry. The anti-TR34-52 bound to platelets as judged by flow cytometry, with the entire gated platelet population showing more fluorescence with anti-TR3452 F(ab'), than with NRS F(ab), ( Table 2 and Fig 5) . Blood was drawn into ACD-A anticoagulant, PRP was prepared, and then the latter was supplemented with 0.1 volume of additional ACD-A. After centrifugation, the platelet pellet was resuspended in HBMT buffer (see Materials and Methods) without MgCI, and gel-filtered. After adding 2 mmol/L MgCI,, the GFP (0.4 mL; -350.000 plateletslpl) was incubated with 100 to 150 pL of anti-TR"." F(ab),, normal rabbit IgG F(ab' ),, or Tris-saline (TS) buffer to achieve the indicated final concentrations, for -30 minutes at 22°C. Aggregation was induced with 0.1 U/mL purified human thrombin. The normal rabbit lgG F(ab), (not shown) did not show any inhibition at concentrations up to 124 pg/mL, but partial inhibition was observed at 250 pg/mL and 500 pg/mL. (B) GFP prepared as in Fig 2A ( 0.45 mL; 334,000 plateletslpl) was incubated with anti-TR"-52 F(ab'), or normal rabbit IgG F(ab'), (35 pL: 250 pg/mL final concentration) for -30 to 60 minutes at 22°C. Aggregation was initiated at the indicated time points with purified human thrombin. The inhibition of aggregation was nearly complete at 0.06 and 0.09 U/mLof thrombin, but inhibition was less evident at 0.1 7 and 0.23 U/mL. However, even at the higher doses the anti-TRwU'" produced a delay in onset of aggregation, a shallower slope of aggregation, and smaller aggregate sire (as judged by the width of the deflections).
signal produced by anti-TR34-52 was considerably less than that produced by antibody 10E5, which was included as a positive control (data not shown). Maximal fluorescence was attained with -100 pg/mL anti-TR3"", suggesting that this is a near saturating concentration; this is in accord with the platelet-aggregation inhibition data. When platelets were preincubated with thrombin (0.1, 1, or 10 U/mL for 5 minutes at 37°C) before the anti-TR3"52 was added, the fluo- on thrombin-induced platelet shape change. Blood was drawn intoO.O1 volume40% sodium citrate and PRP was prepared. EDTA (10 mmol/L final concentration) was added to a portion of the PRP, and antibody 1 OE5 (25 pg/mL), directed against the GPllb/llla receptor, was added to the remainder. The PRP was incubated with 500 pg/mL of normal rabbit lgG F(ab'), or anti-TRY-" F(ab'), for 15 minutes at 22°C and then shape change was initiated with purified human thrombin at 0.1 or 0.2 U/mL.
rescence intensity showed a dose-response reduction; with 10 U/mL thrombin, the fluorescence intensity was actually less than that produced by the NRS F(ab), (Table 2 and Fig  5) . The dose response of the thrombin-induced loss of anti- For anti-TRWSZ F(ab)2 or control NRS F(ab), (1 mg/mLfinal concentrations) and then purified thrombin (1 U/mL final concentration) was added for 1 hour at 37°C. Hirulog (14 pg/mL) was added for 10 minutes to stop the reaction, and then the samples were made 10%
in trichloroacetic acid and placed at 4°C for 1 hour. The precipitated proteins were removed by centrifugation at 12.0009 for 3.5 minutes at 22°C. The supernatant was then mixed with -10 pg of unlabeled TRx-52 that had been partially cleaved with thrombin so that the optical density elution pattern of the partially cleaved TR54-52 could serve to identify the elution of 1251-TRY-52 and its fragments. The mixtures were then subjected to reverse phase HPLC on a C-8 column. Cleavage of the 1251-TRx-52 was extensive in the presence of the NRS F(ab),, with 69% of the radioactivity eluting with the TR3"-5Z peptide. In contrast, the anti-TRx-52 F(ab), prevented thrombin cleavage, with more than 90% of the 1251-TRx-52 remaining intact. Note that the nine amino acid fragment of TR34-52 eluted at -24.5 minutes and so it is not depicted in this elution profile.
intensity produced by the NRS F(ab), . Because activation of megakaryocyte-like cell lines by thrombin has been reported to lead to internalization of the thrombin receptor, 25 we assessed whether the decrease in anti-TR34-52 binding was caused by changes in the receptor as a result of thrombin cleavage or rather, as a result of the platelet activation initiated by the cleavage. To accomplish this, flow cytometry with anti-TR3"j2 was also performed after platelets were treated with sufficient TR42-55 to activate them to approximately the same extent as thrombin, as judged by the surface expression of P-selectin. In contrast to the decrease in fluorescence intensity produced by thrombin treatment, activation by TR42-55 did not produce a decrease in anti-TR3"52 as judged by the fluorescence signal ( Table 2 ). The ability of anti-TR3652 to inhibit changes induced by thrombin cleavage of the receptor was further assessed by flow cytometry. Thus, when anti-TR3",' was preincubated with platelets before thrombin was added, there was virtually no decrease in fluorescence (Fig 5) .
Anti-TR83-94-ELISA assay andflow cytometry. To confirm that the thrombin receptor was not internalized by thrombin activation, studies were conducted with antibody anti-TR83-94, which like anti-TR34-52 is also directed against a region on the receptor's first extracellular domain, but one that is much closer to the transmembrane domain. Anti-TR83-94 reacted positively (OD,, > 0.2) in an ELISA using immobilized TRB3-94 peptide at dilutions of serum up to ]/I60 (data not shown). Anti-TR83-94(250 pg/mL) bound to platelets, as judged by flow cytometry, with the fluorescence intensity produced being slightly greater than that for anti-TR3"52 (Table 2 ). However, in sharp contrast to the results with anti-TR3"j2, when platelets were pretreated with 0.1 or 10.0 U/mL ofthrombin at 37°C for 5 minutes, the decrease in fluorescence intensity of anti-TR83-94 was much less than for anti-TR3"52, and similar to the decrease in intensity with the control IgG (0% and 9% for anti-TR83-94 compared with 42% and 6 I % for anti-TR34-52 and 0% and 4% for the control IgG in experiment 4, and 15% and 25% for anti-TR83-94 compared with 44% and 66% for anti-TR34-52 and 0% and 20% for control IgG in experiment 5).
Monoclonal Antibodies
Immunoreactivity. Approximately 1 20 IgG-positive hybridomas were identified in the initial ELISA screen of hybridoma supernatants with the immunizing antigen. Positive hybridomas were also screened by ELISA using the , and TR5'66 synthetic peptides coated to the wells of 96-well plates to more precisely determine the epitope recognition for each of the secreting clones (Table 3) . Antibody 33-I reacted with TR42-54, but failed to react with C-terminal to the thrombin cleavage site. Antibody 61-1, in contrast, reacted strongly with TR29-43 and only weakly with , suggesting that its dominant epitope was N-terminal to the thrombin cleavage site.
Binding of antibodies to GFP. GFT was reacted with '251-labeled antibodies under various conditions to determine the rate and extent of antibody binding. The time For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Mean fluorescence in arbitrary units.
t Percentage reduction from buffer control in anti-TR34-52 binding compared with reduction produced by 10.0 U/mL thrombin, which is taken as f Percentage increase from control in S-12 binding compared with increase produced by 10 U/mL thrombin. S-12 is an antibody to P-selectin 100%.
(GMP-1 40).
course of binding of 1251-antibody to GFP was measured to determine optimal conditions for equilibrium binding experiments. Subsequently, saturation binding experiments were conducted with increasing amounts of labeled antibody and GFP. The binding of each of the antibodies was found to be specific and saturable. Analysis of the binding data by the method of Scatchard showed that approximately 1,000 to 1,100 antibody molecules bound per platelet at saturation. The I & determined for MoAbs 61-1 and 33-1 were found to be 8.9 and 1 .O nmol/L, respectively. As shown in Fig 6, the addition of EDTA did not affect the binding of the antibodies, nor did the subsequent addition of ADP (20 pmol/L) or collagen (not shown). However, as with the polyclonal anti-TR3"52, there was a dramatic loss of binding of antibodies 61-1 and 33-1 when platelets were pretreated with thrombin at 0.05 U/mL.
DISCUSSION
Anti-TR3'52, a polyclonal rabbit antibody directed against a 20 amino acid peptide encompassing the putative thrombin cleavage site on the thrombin receptor, inhibits thrombin-induced platelet shape change and aggregation, but the inhibition can be overcome with higher concentrations of thrombin. The ability of higher concentrations of thrombin to overcome the inhibition could be consistent with the presence of another thrombin receptor-mediated activation process, but differences in affinity of the receptor for anti-TR34-52 and thrombin might also account for the phenomenon. Anti-TR34-52 does not inhibit platelet shape change and aggregation induced by TR42-52, a peptide derived from the putative new amino terminus after thrombin cleavage. This suggests that anti-TR3"52 does not block the site on the receptor into which the tethered ligand inserts.
Data from epitope mapping studies showed that the antibody reacts with sites on both sides ofthe putative thrombin cleavage site, making it likely, but not certain, that on intact platelets it also reacts with sites on both sides of the cleavage site. Flow cytometry studies confirmed that anti-TR3"52 bound to intact platelets; the fluorescence intensity was of a relatively low level compared with a MoAb to GPIIb/IIIa Immunoreactivity of anti-TR34-52 to GFP before and after thrombin treatment as judged by flow cytometry. Blood was drawn into EDTA anticoagulant (1 0 mmol/L final concentration) and PRP was prepared. After centrifugation, the platelet pellet was resuspended in TSE buffer and gel-filtered (see Materials and Methods). In (A), GFP (388,000 plateletslpl) was incubated with either thrombin (1 0 U/mL final concentration) or TSE for 5 minutes at 37°C. and then Hirulog (50 pg/mL final concentration) for an additional 5 minutes at 37°C. Four-hundred-microliter samples were then incubated with either anti-TR34-52 F(ab), or NRS F(ab), (200 pg/mL final concentrations) for 2 0 minutes at 22%. washed twice with TSE, and incubated with 1/100 dilution of FITC-conjugated F(ab)z fragment of goat antirabbit IgG (F[ab], specific) for 20 minutes at 22°C. The samples were then washed twice with TSE and analyzed by flow cytometry. In (B), GFP was preincubated with either anti-TR34-5z F(ab), or NRS F(ab'), at 200 pg/mLfor 20 minutes at 22°C. and then digested with thrombin (1 0 U/mL) and reacted with FITC-conjugated secondary antibody as above. Note that thrombin pretreatment (A) reduces the binding of anti-TR"-52 to levels below that of control antibody, whereas there is no decrease in anti-TR34'5' binding when GFP is preincubated with anti-TR34-5z and then exposed to thrombin (B).
( 1 OE5)," suggesting a considerably lower copy number for the thrombin receptor than for GPIIb/IIIa. This is consistent with data from Brass et all6 showing that 1,800 molecules of a MoAb to this thrombin receptor bound per platelet at saturation, and our results with antibodies 33-1 and 6 1-1 ( I ,000 to 1,100 molecules per platelet).
We were surprised to find that pretreating platelets with high concentrations of thrombin (10 U/mL) for 5 minutes at 37°C led to nearly complete loss of anti-TR'"'' F(ab'), binding, whereas a similar incubation with thrombin did not affect the binding of the control NRS F(ab),. Because the loss of antibody binding could be caused by thrombininduced platelet activation and receptor redistribution, as has been shown for thrombin receptors on megakaryocyte-like cells lines, 25 or direct thrombin cleavage of the thrombin receptor, we tried to differentiate between these possibilities by assessing the effect of peptide ligand (TR42-55)-induced activation on anti-TR3"52 binding. The peptide ligand caused as much platelet activation as throm- bin, as judged by P-selectin exposure, but did not lead to a loss of anti-TR34-52 binding, suggesting that activation mediated by the thrombin receptor does not lead to receptor internalization. To exclude the possibility that thrombin induces activation phenomena different from those induced by the peptide ligand, we produced an antibody (anti-TR83-94) against a peptide derived from a region of the thrombin receptor's extracellular domain very close to the membrane-spanning region. There was only a minor reduction in anti-TR83-94 binding after thrombin treatment, further indicating that the receptor is not internalized after thrombin cleavage. These data support the hypothesis that loss of the binding of anti-TR34-52 is a consequence of thrombin cleavage ofthe receptor. If anti-TR3"52 truly binds to sites on both sides of the thrombin cleavage site, the loss of anti-TR34-52 binding after thrombin activation suggests that the N-terminal fragment of the thrombin receptor, representing amino acids 26 to 4 1 (amino acids 1 to 25 being a presumed signal peptide),I4 actually leaves the platelet after thrombin cleavage, and that the new tethered ligand region beyond amino acid 42 rapidly enters a protected site in the receptor to which the antibody cannot gain access. Data from our studies with the MoAbs 33-1 (directed at an epitope C-terminal to the thrombin cleavage site) and 61-1 (directed primarily at an epitope N-terminal to the thrombin cleavage site) support this hypothesis, because the binding of both antibodies was dramatically reduced by preincu- 
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bating the platelets with thrombin. However, we would caution, that by their very nature these studies are indirect, and that alternative models may account for these observations.
The relationship between the loss of binding of these antibodies and platelet activation at different thrombin concentrations may provide information on the fraction of receptors that need to be cleaved to achieve different levels of activation. Using anti-TR3"", we found that 0.1 U/mL thrombin, a dose that initiates significant, but submaximal, activation produced about 45% to 78% of the loss of anti-TR3"" binding produced by thrombin at either 1 or 10 U/mL. Of interest, the percentage loss of anti-TR3"52 binding induced by 0.1 and 1.0 U/mL thrombin was nearly identical to the percentage gain in surface P-selectin expression induced by the same concentrations of thrombin.
Although indirect, our data also suggest that the inhibition of thrombin-induced platelet activation by anti-TR34-52 is caused, at least in part, by inhibition ofthrombin cleavage of the receptor: (1) anti-TR34-52 inhibited the cleavage of radiolabeled TR34-52 by thrombin, and ( 2 ) adding thrombin after the anti-TR3"52 was bound to the receptor, did not decrease the amount of anti-TR34-52 on the platelets, as would have been expected if the amino acid 26-4 I fragment (with its attached anti-TR3"52 antibody) left the platelet surface. However, we would point out that the ability of antito inhibit thrombin cleavage of peptide TR3"52 in solution does not necessarily mean that it inhibits cleavage of the receptor on the platelet surface. It is unlikely that the antibody is blocking the site into which the tethered ligand binds because it did not inhibit aggregation induced by the peptide ligand TR42-52. However, it is possible that some of the antibody's effect is a result of attachment to the tethered ligand region such that even if cleavage occurs, the antibody interferes with the insertion of the tethered ligand into its binding site pocket.
On balance, our data provide support for the mechanism of action proposed by Vu et aii4 involving thrombin cleavage at the R41-S42 bond of the receptor. In addition, we provide new data that this cleavage does not result in recep- tor internalization, but does result in loss of the N-terminal peptide and the rapid insertion of the tethered ligand into a protected binding site.
